BofA analyst Greg Harrison raised the firm’s price target on Intellia Therapeutics to $91 from $89 and keeps a Buy rating on the shares following what the firm calls “an impressive update” from its phase 1 trial of NTLA-2002 in hereditary angioedema, or HAE. In addition to incrementally derisking another commercial opportunity, the update provides “further validation to Intellia’s gene editing platform,” contends the firm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $107 from $111 at Chardan
- Intellia Rises on Promising Phase 1 Data in Hereditary Angioedema
- Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors
- Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023
- Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress